OrthoPediatrics(KIDS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company reported a revenue of $61.6 million, a 17% increase compared to Q4 2024 [22] - Full year 2025 revenue growth was 15%, with adjusted EBITDA increasing by nearly 75% [8] - The company generated $10 million in free cash flow in Q4 2025, marking its first positive free cash flow quarter in history [7][28] - The gross profit margin improved to 73% in Q4 2025, up from 68% in Q4 2024 [25] Business Line Data and Key Metrics Changes - The Trauma and Deformity (T&D) business grew by 17% in Q4 2025, driven by strong sales of flagship products [11] - Scoliosis revenue increased by 13% in Q4 2025, supported by international implant growth [24] - The Specialty Bracing (OPSB) business continued to be a strategic growth catalyst, with strong same-store sales growth and successful new product launches [14] Market Data and Key Metrics Changes - U.S. revenue was $48.6 million in Q4 2025, a 13% increase, representing 79% of total revenue [23] - International revenue reached $13.0 million, a 33% increase, accounting for 21% of total revenue [23] - The company experienced strong demand in direct markets in the EU and Australia, with a rebound in Latin America [19] Company Strategy and Development Direction - The company aims to help 1 million children annually and is focused on expanding its product portfolio and market presence [9] - A multi-year product innovation cycle is underway, with significant product launches planned [10] - The company is exploring opportunities in pediatric subspecialties beyond orthopedics, including cardiovascular technologies [44][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining revenue growth and achieving cash flow breakeven in 2026 [8][28] - The company anticipates continued share gains and improved EBITDA margins driven by new product launches [10][11] - Management highlighted the importance of the EU MDR approvals for expanding product offerings in Europe [20][88] Other Important Information - The company recorded a GAAP net loss per share of $0.43 in Q4 2025, an improvement from $0.69 in the prior year [26] - Non-GAAP net loss per share was $0.30, compared to $0.29 in the same period last year [27] - The company is committed to maintaining a strong R&D pipeline, with several innovative products expected to launch in the coming years [80] Q&A Session Summary Question: Insights on Scoliosis performance and competitive pressure - Management noted strong performance in the Scoliosis segment, driven by the VerteGlide system and new product launches, with expectations for continued growth [33][34] Question: Outlook on margin progression - Management indicated that gross margins are expected to remain around 73% in 2026, with adjusted EBITDA projected to increase significantly [36] Question: Exploration of options to increase shareholder value - Management emphasized the potential for expanding the commercial footprint into other pediatric subspecialties, leveraging existing infrastructure [42][44] Question: Updates on 7D placements and strategy - Management reported normal growth in 7D placements, with optimism for 2026 based on strong performance in existing accounts [55] Question: Impact of new product launches on guidance - Management stated that while there is significant interest in new products, minimal revenue from these launches is included in the 2026 guidance [57] Question: Pricing and margin impact from new products - Management confirmed that new technologies are commanding higher premiums, which will positively impact profitability over time [87] Question: EU MDR strategy and market penetration - Management highlighted the importance of having a full range of product sizes approved in Europe, which will facilitate surgeon conversions and drive growth [88] Question: Cardiovascular business margin profile - Management indicated that the gross margin profile for the cardiovascular business is expected to be higher than the current implant business, which is encouraging for future profitability [90]